Editas Medicine, Inc. EDIT | NASDAQ
|2026-09-09
Company Overview:
10 Year EDIT Performance Metrics:
Build Custom Charts
EDIT Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for EDIT
Based on past 10-year performance, here are EDIT growth metrics:
Share price CAGR of -15.35%
Dividend CAGR of +0%
Using EDIT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| EDIT (DRIP) | EDIT - No DRIP | |
|---|---|---|
| Current Price | $2.67 | $2.67 |
| Start Shares | 3,745.32 | 3,745.32 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 3,745.32 | 3,745.32 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $0.50 | $2.67 |
| Total Dividends | $0 | $0 |
| Final Value | $1,888 | $10,000 |
NOTE: Above numbers are our estimate based on EDIT's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Editas Medicine, Inc. (EDIT) had its IPO on , and is traded on NASDAQ stock exchange.
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases. The company’s work centers on CRISPR-based technologies, including Cas9 and Cas12a, which it uses to design precise therapies for genetically driven conditions. Its current development efforts include in vivo and ex vivo programs aimed at areas such as hematology, cardiovascular disease, and other severe disorders with limited treatment options. Editas Medicine also maintains collaborations and intellectual property positions that support its research platform and pipeline. Headquartered in Cambridge, Massachusetts, the company plays a specialized role in the gene editing market by advancing experimental medicines intended to address diseases at the DNA level.
EDIT website: https://www.editasmedicine.com
DCF Model — EDIT
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
